We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.22%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$740M
AUM Growth
+$30.5M
Cap. Flow
-$239M
Cap. Flow %
-32.31%
Top 10 Hldgs %
67%
Holding
218
New
56
Increased
59
Reduced
50
Closed
36

Top Buys

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$40.7M
2
SLAI
SOLAI Ltd ADS
SLAI
+$15.2M
3
VRPX
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
+$7.02M
4
FLUX icon
Flux Power
FLUX
+$6.05M
5
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.87M

Top Sells

Rank Stock Value
1
LNAI
Lunai Bioworks
LNAI
+$7.71M
2
ATOS icon
Atossa Therapeutics
ATOS
+$4.06M
3
ATER icon
Aterian
ATER
+$4M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$2.95M
5
RDHL
Redhill Biopharma
RDHL
+$2.34M

Sector Composition

Rank Sector Weight
1 Healthcare 6.89%
2 Financials 5.45%
3 Technology 3.65%
4 Industrials 1.84%
5 Communication Services 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXMD icon
201
TherapeuticsMD
TXMD
$23.8M
– –
-12,500
Closed -$744K
ZVRA icon
202
CALL
Zevra Therapeutics
ZVRA
$575M
– –
-1,735
Closed -$2.22M
CSCI
203
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
-2,442
Closed -$214K
CSCI
204
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
-9
Closed -$81K
NTBL
205
PUT
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
– –
-14
Closed -$117K
ASXC
206
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-931,414
Closed -$2.95M
ASXC
207
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-5,594
Closed -$1.77M
MMAT
208
PUT
DELISTED
Meta Materials Inc. Common Stock
MMAT
– –
-2
Closed -$136K
BETS
209
DELISTED
Bit Brother Limited Class A Ordinary Shares
BETS
– –
-69
Closed -$2.29M
POL.WS
210
DELISTED
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
– –
-180,000
Closed -$385K
BIOC
211
DELISTED
Biocept, Inc.
BIOC
– –
-2,563
Closed -$322K
BIOC
212
PUT
DELISTED
Biocept, Inc.
BIOC
– –
-39
Closed -$486K
AGTC
213
PUT
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-1,545
Closed -$604K
ODT
214
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-14,979
Closed -$52K
ADMS
215
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-553
Closed -$61K
ADMS
216
PUT
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-5,168
Closed -$568K
CVM.WS
217
PUT
DELISTED
Cel-Sci Corp Series S
CVM.WS
– –
-1,916
Closed -$1.66M
5 6 7 8
9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sabby Management held 218 positions worth $740M, up 4.3% from $709M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $239M in Q3 2021, closing 36 positions and reducing 50 holdings. Its most notable exit was Atossa Therapeutics, an estimated $4.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.9% of assets, down from 10% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Bit Digital worth $30.5M.

  • Sabby Management's largest Q3 2021 buy was Bit Digital: 4,216,310 shares worth $30.5M.
  • Sabby Management added most to Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021, an estimated $7.02M increase.
  • Sabby Management's biggest Q3 2021 reduction was Lunai Bioworks, cutting an estimated $7.71M.
  • Sabby Management fully exited Atossa Therapeutics in Q3 2021, selling an estimated $4.06M.
  • Sabby Management's ten largest holdings make up 67% of its $740M portfolio in Q3 2021.
  • Sabby Management opened 56 new positions and closed 36 in Q3 2021.
  • Sabby Management's portfolio value rose 4.3% quarter-over-quarter to $740M.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.